RYTELOTM (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 ...
Biologics by McKesson selected by Geron Corp. as a specialty pharmacy provider for RYTELO™ (imetelstat), a telomerase inhibitor for treating low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. RYTELO, approved by the FDA on June 6, 2024, inhibits telomerase activity, preventing telomere binding. Biologics by McKesson is committed to providing innovative, high-touch care for patients.
Reference News
Biologics by McKesson selected by Geron Corp. as a specialty pharmacy provider for RYTELO™ (imetelstat), a telomerase inhibitor for treating low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. RYTELO, approved by the FDA on June 6, 2024, inhibits telomerase activity, preventing telomere binding. Biologics by McKesson is committed to providing innovative, high-touch care for patients.